Cell Signaling Technology

Product Pathways - Chromatin Regulation

Histone Deacetylase 1 (HDAC1) Antibody #2062

Applications Reactivity MW (kDa) Source
W IP H M R Mk 62 Rabbit

Applications Key:  W=Western Blotting  IP=Immunoprecipitation
Reactivity Key:  H=Human  M=Mouse  R=Rat  Mk=Monkey
Species enclosed in parentheses are predicted to react based on 100% sequence homology. Species cross-reactivity is determined by Western blot.

Specificity / Sensitivity

Histone Deacetylase 1 (HDAC1) Antibody detects endogenous levels of total HDAC1 protein. The antibody does not cross-react with other HDAC proteins.

Source / Purification

Polyclonal antibodies are produced by immunizing rabbits with a synthetic peptide (KLH-coupled) corresponding to the carboxy-terminal sequence of human HDAC1. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of COS or HeLa cell lysates using Histone Deacetylase 1 (HDAC1) Antibody.

Background

Acetylation of the histone tail causes chromatin to adopt an "open" conformation, allowing trans factors increased accessibility to DNA. The identification of histone acetyltransferases (HATs) and their large multiprotein complexes has yielded important insights into how these enzymes regulate transcription (1,2). HAT complexes interact with sequence-specific activator proteins to target specific genes. In addition to histones, HATs can acetylate non-histone proteins, suggesting multiple roles for these enzymes (3). In contrast, histone deacetylation promotes a "closed" chromatin conformation and typically leads to repression of gene activity (4). Mammalian histone deacetylases can be divided into three classes on the basis of their similarity to various yeast deacetylases (5). Class I (HDACs 1, 2, 3 and 8) proteins are related to the yeast Rpd3-like proteins, those in class II (HDACs 4, 5, 6, 7, 9 and 10) are related to yeast Hda1-like proteins and class III proteins are related to the yeast protein Sir2. Inhibitors of HDAC activity are now being explored as potential therapeutic cancer agents (6,7).

  1. Marmorstein, R. et al. (2001) Cell. Mol. Life Sci. 58, 693-703.
  2. Gregory, P.D. et al. (2001) Exp. Cell Res. 265, 195-202.
  3. Liu, Y. et al. (2000) Mol. Cell. Biol. 20, 5540-5543.
  4. Cress, S.D. and Seto, E. (2000) J. Cell. Physiol. 184, 1-16.
  5. Gray, S.G. and Ekstrom, T.J. (2001) Exp. Cell Res. 262, 75-83.
  6. Thiagalingam, S. et al. (2003) Ann. N. Y. Acad. Sci. 983, 84-100.
  7. Viguishin, D.M. and Coombes, R.C. (2004) Curr. Cancer Drug Targets 4, 205-218.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

Product Pathways

Drug Discovery Tools

Featured Technologies

Protein Classes